Cytokinetics Inc (CYTK)

14.20
0.05 0.35
NASDAQ : Health Care
Prev Close 14.25
Open 14.25
Day Low/High 14.03 / 14.38
52 Wk Low/High 5.90 / 13.18
Volume 108.17K
Avg Volume 471.30K
Exchange NASDAQ
Shares Outstanding 53.67M
Market Cap 759.38M
EPS 0.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

CYTK October 20th Options Begin Trading

Investors in Cytokinetics Inc saw new options become available today, for the October 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CYTK options chain for the new October 20th contracts and identified one put and one call contract of particular interest.

Cytokinetics Announces Baseline Data From First Cohort Of Phase 2 Clinical Trial Of CK-2127107 In Patients With SMA

Cytokinetics Announces Baseline Data From First Cohort Of Phase 2 Clinical Trial Of CK-2127107 In Patients With SMA

Patient Demographics Presented at Cure SMA 2017 Annual SMA Conference

Cytokinetics is Now Oversold (CYTK)

Cytokinetics is Now Oversold (CYTK)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Cytokinetics Announces Start Of Phase 1b Clinical Trial Of CK-2127107 In Elderly Subjects With Limited Mobility

Cytokinetics Announces Start Of Phase 1b Clinical Trial Of CK-2127107 In Elderly Subjects With Limited Mobility

Trial Designed to Assess Effects of Skeletal Muscle Activation on Measures of Muscle Strength and Endurance Under Collaboration with Astellas

First Week of February 2018 Options Trading For Cytokinetics (CYTK)

Investors in Cytokinetics Inc saw new options become available this week, for the February 2018 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 239 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

First Week of July 21st Options Trading For Cytokinetics (CYTK)

Investors in Cytokinetics Inc saw new options begin trading this week, for the July 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CYTK options chain for the new July 21st contracts and identified one put and one call contract of particular interest.

Biotech Movers: Anika Up on Strong Analyst Ratings

Biotech Movers: Anika Up on Strong Analyst Ratings

Anika focuses on pain management, tissue regeneration and wound healing.

Merger Buzz Drives Akorn to Top of Health Chart in April

Merger Buzz Drives Akorn to Top of Health Chart in April

Other industry list-toppers included MiMedx, Cytokinetics, C.R. Bard, and Spectrum.

Interesting CYTK Put And Call Options For June 16th

Investors in Cytokinetics Inc saw new options begin trading this week, for the June 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CYTK options chain for the new June 16th contracts and identified one put and one call contract of particular interest.

Cytokinetics Added To S&P SmallCap 600

Arena Takes a Beating After Lackluster Secondary, Cytokinetics Pops: Biotech Movers

Arena Takes a Beating After Lackluster Secondary, Cytokinetics Pops: Biotech Movers

Arena Pharmaceuticals, Rigel Pharmaceuticals and Cytokinetics were among the biotech stock movers in premarket trading on Tuesday.

First Week of CYTK November 17th Options Trading

Investors in Cytokinetics Inc saw new options become available this week, for the November 17th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 225 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

TheStreet Quant Rating: C (Hold)